SG11202105125XA - Macrocyclic compound and use thereof - Google Patents

Macrocyclic compound and use thereof

Info

Publication number
SG11202105125XA
SG11202105125XA SG11202105125XA SG11202105125XA SG11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA
Authority
SG
Singapore
Prior art keywords
macrocyclic compound
macrocyclic
compound
Prior art date
Application number
SG11202105125XA
Inventor
Shigemitsu Matsumoto
Ryoma Hara
Naoyoshi Noguchi
Hideto Fukushi
Ayumu Niida
Satoshi Sasaki
Minoru Ikoma
Toshitake Kobayashi
Tsuyoshi Maekawa
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of SG11202105125XA publication Critical patent/SG11202105125XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
SG11202105125XA 2018-12-05 2019-12-04 Macrocyclic compound and use thereof SG11202105125XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
SG11202105125XA true SG11202105125XA (en) 2021-06-29

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105125XA SG11202105125XA (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Country Status (17)

Country Link
US (1) US11518763B2 (en)
EP (1) EP3890738A4 (en)
JP (1) JP2022510736A (en)
KR (1) KR20210099622A (en)
CN (1) CN113164468A (en)
AR (1) AR117251A1 (en)
AU (1) AU2019391942B2 (en)
BR (1) BR112021010704A2 (en)
CA (1) CA3121952A1 (en)
CL (1) CL2021001451A1 (en)
CO (1) CO2021007304A2 (en)
MX (1) MX2021006527A (en)
PH (1) PH12021551262A1 (en)
SG (1) SG11202105125XA (en)
TW (1) TWI820266B (en)
UA (1) UA127872C2 (en)
WO (1) WO2020116660A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126950C2 (en) 2018-08-20 2023-02-22 Янссен Фармацевтика Нв Inhibitors of keap1-nrf2 protein-protein interaction
KR20230104126A (en) * 2020-09-14 2023-07-07 사노피 Tetrahydroisoquinoline derivatives for the treatment of red blood cells and inflammatory diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2606622C2 (en) 2010-08-31 2017-01-10 Бионуре Фарма, С.Л. Agonists of neurotrophin receptors and their use as medicaments
EP3010892B8 (en) 2013-06-21 2019-05-22 Karyopharm Therapeutics Inc. 1,2,4-triazoles as nuclear transport modulators and uses thereof
CA2934216C (en) 2013-12-18 2021-03-16 Glaxosmithkline Intellectual Property Development Limited Substitued phenyl or benzyl propanote derivatives and pharmaceutical compositiions thereof useful as nrf2 regulators
PT3307739T (en) 2015-06-15 2021-01-04 Glaxosmithkline Ip Dev Ltd Nrf2 regulators
CA2988374A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
RU2018101077A (en) 2015-06-15 2019-07-15 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед REGULATORS NRF2
CA2995325A1 (en) 2015-08-12 2017-02-16 Mochida Pharmaceutical Co., Ltd. Isothiazole derivative
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
JP2018529745A (en) 2015-10-06 2018-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Biarylpyrazoles as NRF2 regulators
US20200031820A1 (en) 2016-12-12 2020-01-30 Glsxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2848699T3 (en) 2016-12-14 2021-08-11 Glaxosmithkline Ip Dev Ltd 3-Oxo-1,4-diazepinyl compounds as activators of NRF2
US11078216B2 (en) 2016-12-14 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as NRF2 activators
WO2018109643A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 acti
US11059816B2 (en) 2016-12-15 2021-07-13 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as NRF2 activators
CN110114361B (en) 2016-12-15 2022-04-12 葛兰素史密斯克莱知识产权发展有限公司 NRF2 compound
AR110590A1 (en) 2016-12-27 2019-04-10 Biogen Ma Inc NRF2 ACTIVATOR
WO2018140738A1 (en) 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf 2 activator
EP3573968A1 (en) * 2017-01-30 2019-12-04 Biogen MA Inc. Nrf2 activator
JP2020097526A (en) * 2017-03-28 2020-06-25 武田薬品工業株式会社 Heterocyclic compound

Also Published As

Publication number Publication date
JP2022510736A (en) 2022-01-27
CL2021001451A1 (en) 2021-12-24
CN113164468A (en) 2021-07-23
WO2020116660A1 (en) 2020-06-11
UA127872C2 (en) 2024-01-31
US11518763B2 (en) 2022-12-06
CO2021007304A2 (en) 2021-06-21
MX2021006527A (en) 2021-07-21
PH12021551262A1 (en) 2021-10-25
AU2019391942A1 (en) 2021-06-03
US20220119391A1 (en) 2022-04-21
TWI820266B (en) 2023-11-01
AR117251A1 (en) 2021-07-21
BR112021010704A2 (en) 2021-08-24
EP3890738A4 (en) 2022-08-17
AU2019391942B2 (en) 2024-03-21
EP3890738A1 (en) 2021-10-13
CA3121952A1 (en) 2020-06-11
KR20210099622A (en) 2021-08-12
TW202039494A (en) 2020-11-01

Similar Documents

Publication Publication Date Title
IL271964A (en) Macrocyclic compounds and uses thereof
IL285178A (en) Compounds and uses thereof
IL288991A (en) Macrocyclic compound and uses thereof
EP3826721C0 (en) Naphthyridine compounds and uses thereof
IL285177A (en) Compounds and uses thereof
IL284514A (en) Halo-allylamine compounds and use thereof
IL277502A (en) Compounds and uses thereof
IL286497A (en) Compounds and uses thereof
IL280644A (en) Magnesium-serinate compound and use thereof
IL279483A (en) Cyanotriazole compounds and uses thereof
IL291499A (en) Aza-quinoline compounds and uses thereof
IL284764A (en) Compounds and uses thereof
IL285118A (en) Compounds and uses thereof
SG11202105125XA (en) Macrocyclic compound and use thereof
IL277749A (en) Pladienolide compounds and their use
GB201801102D0 (en) New compounds and uses
EP4051270A4 (en) 4-amino-imidazoquinoline compounds and use thereof
GB201806349D0 (en) New compounds and uses
GB201810121D0 (en) Macrocyclic compounds and uses thereof
IL283540A (en) Dock1-inhibiting compound and use thereof
GB201908967D0 (en) Macrocyclic compounds and uses thereof
ZA202201239B (en) Aminothiolester compounds and uses thereof
SI3683215T1 (en) Tetrazolinone compound and use thereof
GB201810667D0 (en) New compounds and uses
GB201813311D0 (en) Novel compounds and their use